NATHAN REYELTS: Open Payments
NPI 1932183084 · FAIRMONT, MN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$249 in 15 payments from 11 companies in 2025. Trend: 2023 $252 · 2024 $237 · 2025 $249
Food & beverage: $249
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Amgen Inc. | 2 | $28 |
| Surgenex LLC | 1 | $23 |
| ACADIA Pharmaceuticals Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| ABBVIE INC. | 1 | $14 |
Products named: AUSTEDO XR, CAPLYTA, NEXLETOL, SurGraft, NUPLAZID, KEVEYIS, ZEPBOUND, ImmunoCAP.
Industry payments across MN — which companies pay providers there.
